NGEN NervGen Pharma Corp.
NervGen Pharma Corp. (NGEN) is confirmed to report earnings on November 16, 2026, before the market open. The consensus earnings estimate is a loss of $0.10 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About NervGen Pharma Corp.
Nanogen, Inc. integrates advanced microelectronics and molecular biology into a core technology platform with broad and diverse commercial applications in the fields of genomics and biomedical research, medical diagnostics, drug discovery, forensics, agriculture, environmental testing and potentially the electronics and telecommunications industries.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.